83
Participants
Start Date
May 31, 2012
Primary Completion Date
February 28, 2013
Study Completion Date
March 31, 2013
placebo/dalfampridine-ER
Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
dalfampridine-ER/placebo
Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
Acorda Site #004, White Plains
Acorda Site #007, West Haverstraw
Acorda Site #019, Buffalo
Acorda Site #001, Philadelphia
Acorda Site #008, Norfolk
Acorda Site #013, Charlotte
Acorda Site #003, Decatur
Acorda Site #015, Fort Lauderdale
Acorda Site #002, Atlantis
Acorda Site #011, Birmingham
Acorda Site #021, Lexington
Acorda Site #017, Saginaw
Acorda Site #020, Great Falls
Acorda Site #023, Reno
Acorda Site #018, La Jolla
Acorda Site #016, Newport Beach
Acorda Site #010, Bellevue
Acorda Site #006, Fairfield
Acorda Site #009, Boston
Acorda Site #022, New Brunswick
Lead Sponsor
Acorda Therapeutics
INDUSTRY